Silybin/Silymarin treatment in chronic hepatitis C

Autores: Barbero Becerra Varenka J, Méndez Sánchez Nahum


Article commented Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy. A randomized controlled trial. JAMA 2012; 308(3): 274-82. Comments Chronic HCV infection leads to cirrhosis and hepatocellular carcinoma and causes more than 300,000 deaths per year. Current treatment is based on a combination of pegylated interferon (Peg-IFN) and ribavirin in combination with oral protease inhibitors of HCV like boceprevir and telaprevir, which directly inhibits HCV replication and drives progressive infected cell clearance through intricate and only partly understood mechanisms. Multidrug resistance represents an increasing problem in the treatment of several diseases. It often appears after prolonged exposure of cells to a single drug and is characterized by cells resistance to structurally unrelated compounds. It has been demonstrated that current therapy could eradicate just certain HCV genotypes. In addition, certain limitations associated with current treatment as side effects and poor response leads to the need to search better anti-HCV therapies.

Palabras clave:

2012-08-21   |   534 visitas   |   Evalua este artículo 0 valoraciones

Vol. 11 Núm.5. Septiembre-Octubre 2012 Pags. 731-733 Ann Hepatol 2012; 11(5)